Rothschild & CO Asset Management Us Inc. Blueprint Medicines Corp Transaction History

Rothschild & CO Asset Management Us Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$92.08 - $124.48 $21.1 Million - $28.5 Million	-228,940 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$66.45 - $92.7 $2.67 Million - $3.72 Million	-40,109 Reduced 14.91%	228,940 $21.2 Million
Q2 2020 Aug 10, 2020	BUY	$57.09 - $79.27 $9.43 Million - $13.1 Million	165,128 Added 158.9%	269,049 $21 Million
Q1 2020 May 14, 2020	BUY	$48.11 - $82.22 $347,017 - $593,052	7,213 Added 7.46%	103,921 $6.08 Million
Q4 2019 Feb 12, 2020	SELL	$66.73 - $82.59 $354,269 - $438,470	-5,309 Reduced 5.2%	96,708 $7.75 Million
Q3 2019 Nov 08, 2019	BUY	$72.9 - $101.41 $7.44 Million - $10.3 Million	102,017 New	102,017 $7.5 Million

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.3B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.